The Indian Practitioner

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

From Darkness to Light : Clinical Insights on Melatonin


Affiliations
1 Medical & Regulatory Affairs, Aristo Pharmaceuticals Private Limited, 23-A Shah Industrial Estate, Andheri, Mumbai, India
2 Scientific Department, Aristo Pharmaceuticals Private Limited, India
     

   Subscribe/Renew Journal


Melatonin also known as ‘sleep hormone’ is synthesized and released from the pineal gland in response to the luminous information. Melatonin primarily contributes to the regulation of biological rhythms and induction of sleep. Apart from this, due to its inherent anti-oxidant property, it is known to impart protection to various tissues. In addition, it also exhibits multiplicity of physiological effects all over the body. At therapeutic level, Melatonin is used for the management of primary as well as secondary sleep disorders, jet lag, and synchronization of cardiac rhythms. Additionally, due to its pleiotropic benefits it is used in various disorders.

Keywords

Melatonin, Sleep Disorders, Pleiotropic Benefits, Therapeutic Benefits.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Chowdhury I, Maitra S. Melatonin: Fifty Years of Scientific Journey from the Discovery in Bovine Pineal Gland to Delineation of Functions in Human, Indian Journal of Biochemistry & Biophysics.2008; 45:289-304.

  • Pevet P. Melatonin Dialogues in Clinical Neuroscience. 2002; 4:57-72.

  • Tordjman S, Chokron S, Delorme R, et al. Current Neuropharmacology. 2017; 15:434- 443.

  • Emet M, Ozcan H, Yayla M, et al. A Review of Melatonin, Its Receptors and Drugs. Eurasian J Med. 2016; 48:135-41.

  • Feingold KR, Anawalt B, Boyce A, et al. Physiology of the Pineal Gland and Melatonin – Endotext. 2000.

  • Srinivasan V, Trahkt I, Spence D, et al. Melatonin and melatonergic drugs on Sleep: possible mechanisms of action. International Journal of Neuroscience. 2009; 119:821-846.

  • Khullar A. The Role of Melatonin in the Circadian Rhythm Sleep-Wake Cycle. Psychiatric Times. 2012; 29:1-8.

  • Zisapel N. New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation British Journal of Pharmacology. 2018; 175:3190–3199.

  • ZizhenXie, Fei Chen, William A, et al. A review of sleep disorders and melatonin. Neurological Research. 2017:1-8.

  • Shechter A, Lespérance P, Ying Kin N, et al. Nocturnal polysomnographic sleep across the menstrual cycle in premenstrual dysphoric disorder Sleep Med. 2012;13:1071–1078.

  • Scheer F, Morris C, Garcia J, et al. Repeated Melatonin Supplementation Improves Sleep in Hypertensive Patients Treated with Beta-Blockers: A Randomized Controlled TrialSleep. 2012; 35:1395–1402.

  • Lemoine J, Nir T, Laudon M, et al. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res. 2007; 16:372-380.

  • Luthringer R, Muzet M, Zisapel N, et al. The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia IntClinPsychopharmacol. 2009; 24:239-249.

  • Wade A G, Ford I, Crawford G, et al. Efficacy of prolonged release melatonin in insomnia patients aged 55–80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin. 2007; 23:2597-2605.

  • Roberto C, Mendonça L, Nicolas A, et al. The benefits of four weeks of melatonin treatment on circadian patterns in resistance-trained athletes. Chronobiology International. 2015; 32:1125–1134.

  • Mundey K, Benloucif S, Harsanyi K, et al. Phase-Dependent Treatment of Delayed Sleep Phase Syndrome with Melatonin. Sleep. 2005; 28:1271-1278.

  • Dahlitz M, Alvarez B, Vignau J, et al. Delayed sleep phase syndrome response to melatonin. Lancet. 1991; 337:1121-1124.

  • Kayumov L, Brown G, Jindal R, et al. A Randomized, Double-Blind, Placebo-Controlled Crossover Study of the Effect of Exogenous Melatonin on Delayed Sleep Phase Syndrome. Psychosom Med. 2001; 63:40e8.

  • Haghighi K S, Aminian O, Pouryaghoub G, et al. Efficacy and hypnotic effects of melatonin in shift-work nurses: double-blind, placebo-controlled crossover trial J Circadian Rhythms. 2008; 6:1-5.

  • Sack R, Auckley D, Auger R, et al. Circadian Rhythm Sleep Disorders: Part I, Basic Principles, Shift Work and Jet Lag Disorders. Sleep. 2007; 30:1460-83.

  • Herxheimer A, Petrie K. Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev. 2002:1-9.

  • Petrie K, Dawson A, Thompson L, et al. A Double-Blind Trial of Melatonin as a Treatment for Jet Lag in International Cabin Crew. Biol Psychiatry. 1993; 33:526-30.

  • McCarter S, Boswell C, St. Louis E, et al. Treatment outcomes in REM sleep behavior disorder. Sleep Med. 2013; 14:237–242.

  • McGrane I, Leung J, St. Louis E, et al.Melatonin therapy for REM sleep behavior disorder: a critical review of evidence. Sleep Med. 2015; 16:19–26.

  • Kunz D, Mahlberg R. A two-part, double-blind, placebocontrolled trial of exogenous melatonin in REM sleep behaviour disorder. J Sleep Res. 2010; 19:591-596.

  • Sack R, Brandes R, Kendali A, et al. Entrainment of freerunning circadian rhythms by melatonin in blind people. N Engl J Med. 2000; 343:1070-1077.

  • Hack L, Lockley S, Arendt J, et al. The Effects of Low-Dose 0.5-mg Melatonin on the Free-Running Circadian Rhythms of Blind Subjects. J Biol Rhythms.2003;18:420-429.

  • Rockville. AHRQ Evidence Report Summaries. Agency for Healthcare Research and Quality (US); 1998-2005.

  • Tian Li, Shuai J, Mengzhen H, et al. Exogenous melatonin as a treatment for secondary sleep disorders: a systematic review and meta-analysis Front Neuroendocrinol. 2019; 52:22-28.

  • Cardinali D, Brusco L, Liberczuk C, et al. The use of melatonin in Alzheimer’s disease. Neuro Endocrinol Lett. 2002; 23:20-3.

  • Furio A, Brusco L, Cardinali D. Possible therapeutic value of melatonin in mild cognitive impairment: a retrospective study. J. Pineal Res. 2007; 43:404-409.

  • Zaslavskaia R, Komarov F, Shakirova A, et al. Effect of moxonidine monotherapy and in combination with melatonin on hemodynamic parameters in patients with arterial hypertension. Klin Med. 2000; 78:41-44.

  • Dowling G, Mastickb, Colling E, et al. Melatonin for sleep disturbances in Parkinson’s disease. Sleep Med. 2005; 6:459-466.

  • Peled N, Shorer Z, Peled E, et al. Melatonin for sleep disturbances in Parkinson’s disease. Epilepsia. 2001;42(9):1208-1210.

  • Dolberg O, Hirschmann S, Grunhaus H. Melatonin for the Treatment of Sleep Disturbances in Major Depressive Disorder Am. J.Psychiatry. 1998; 155:1119-1121.

  • Leppamaki S, Partonen T, Vakkuri O, et al. Effect of controlled-release melatonin on sleep quality, mood, and quality of life in subjects with seasonal or weather-associated changes in mood and behavior. Eur. Neuropsychopharmacology. 2003; 13:137-145.

  • Weiss M, Wasdell M, Bomben M, et al. Sleep Hygiene and Melatonin Treatment for Children and Adolescents with ADHD and Initial Insomnia. J. Am. Acad. Child Adolesc. Psychiatry. 2006; 45:512-519.

  • Carminati G, Deriaz N, Bertschy G. Melatonin in the treatment of chronic sleep disorders in adults with autism: a ret rospective study. Swiss Med. Wkly. 2009; 139:293-296.

  • Braam W, Smits M G, Didden R, et al. Exogenous melatonin for sleep problems in individuals with intellectual disability: a meta-analysis. Developmental Medicine and Child Neurology. 2009; 51:340-349.

  • Mahmood D. Pleiotropic Effects of Melatonin. Drug Res (Stuttg). 2019; 69:65-74.

  • Long R, Zhu Y, Zhou S. Therapeutic role of melatonin in migraine prophylaxis: A systematic review. Medicine (Baltimore). 2019;98: e14099.

  • Lyon C, Langner S. PURLs: Consider melatonin for migraine prevention. J FamPract. 2017; 66:320-322.

  • Lawson K. Is there a role for melatonin in fibromyalgia? AIMS Molecular Science, 2019;6:73-86.

  • Miroddi M, Bruno R, Galletti F, et al. Clinical pharmacology of melatonin in the treatment of tinnitus: a review. Eur J ClinPharmacol. 2015; 71:263-70.

  • Lundmark P, Pandi-Perumal S, Srinivasan V, et al. Role of melatonin in the eye and ocular dysfunctions. Visual Neuroscience, 2006; 23:853-862.

  • Rosenstein R, Pandi-Perumal, S, Srinivasan V, et al. Melatonin as a therapeutic tool in ophthalmology: implications for glaucoma and uveitis. J. Pineal Res. 2010; 49:1–13.

  • Awad-Alkoziv H. Melatonin and melanopsin in the eye: friends or foes? An Real Acad Farm. 2019; 85:49-59.

  • Siah KT, Wong RK, Ho KY. Melatonin for the treatment of irritable bowel syndrome. World J Gastroenterol. 2014; 20:2492-2498.

  • BahrampourJuybari K, Pourhanifeh MH, et al. Melatonin potentials against viral infections including COVID-19: Current evidence and new findings. Virus Res. 2020; 287:198108.

  • Zhang R, Wang X, Ni L, et al. COVID-19: Melatonin as a potential adjuvant treatment. Life Sci. 2020; 250:117583.

  • Castillo RR, Quizon GRA, Juco MJM, et al. Melatonin as adjuvant treatment for coronavirus disease 2019 pneumonia patients requiring hospitalization (MAC-19 PRO): a case series. Melatonin Research. 2020; 3:297-310.

  • Gonçalves AL, Martini Ferreira A, Ribeiro RT, et al. Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention. J NeurolNeurosurg Psychiatry. 2016; 87:1127-1132.

  • Peres MF, Zukerman E, da Cunha Tanuri F, et al. Melatonin, 3 mg, is effective for migraine prevention. Neurology. 2004; 63:757.

  • Hurtuk A, Dome C, Holloman CH, et al. Melatonin: can it stop the ringing? Ann OtolRhinolLaryngol. 2011; 120:433-40.

  • Ismail SA, Mowafi HA. Melatonin provides anxiolysis, enhances analgesia, decreases intraocular pressure, and promotes better operating conditions during cataract surgery under topical anesthesia. AnesthAnalg. 2009; 108:1146-1151.

  • Samples JR, Krause G, Lewy AJ. Effect of melatonin on intraocular pressure. Curr Eye Res. 1988; 7:649-53.


Abstract Views: 167

PDF Views: 0




  • From Darkness to Light : Clinical Insights on Melatonin

Abstract Views: 167  |  PDF Views: 0

Authors

Manish Maladkar
Medical & Regulatory Affairs, Aristo Pharmaceuticals Private Limited, 23-A Shah Industrial Estate, Andheri, Mumbai, India
Ashok Yadav
Scientific Department, Aristo Pharmaceuticals Private Limited, India
Sonal Kamble
Scientific Department, Aristo Pharmaceuticals Private Limited, India

Abstract


Melatonin also known as ‘sleep hormone’ is synthesized and released from the pineal gland in response to the luminous information. Melatonin primarily contributes to the regulation of biological rhythms and induction of sleep. Apart from this, due to its inherent anti-oxidant property, it is known to impart protection to various tissues. In addition, it also exhibits multiplicity of physiological effects all over the body. At therapeutic level, Melatonin is used for the management of primary as well as secondary sleep disorders, jet lag, and synchronization of cardiac rhythms. Additionally, due to its pleiotropic benefits it is used in various disorders.

Keywords


Melatonin, Sleep Disorders, Pleiotropic Benefits, Therapeutic Benefits.

References